Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion.
BACKGROUND
To compare the long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion with that of aspirin.


METHODS
A randomized controlled clinical trial was conducted on patients with central retinal vein occlusion of less than 30 days duration. Patients in the dalteparin group received subcutaneous dalteparin 100 IU/kg twice a day for 10 days, and then 100 IU/kg once a day for another ten days. In the aspirin group the patients received 100 mg aspirin daily throughout the study.


RESULTS
Forty seven patients were enrolled, 24 in the dalteparin group and 23 in the aspirin group, and were followed up for one year. One (4.1%) of the 24 patients in dalteparin group, and 9 (39.1%) of 23 patients in aspirin group developed iris neovascularization. the difference was significant (P=0.0001). The visual outcomes of the two groups were compared, and a significant difference was found (P=0.016).


CONCLUSIONS
Patients treated with dalteparin within 30 days of the onset of central retinal vein occlusion were less likely to develop neovascularization of iris. There was also a significant difference in the visual acuity between two groups.
Farahvash
Mohammad Sadegh
MS
Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran. Farahva@yahoo.com
Farahvash
Mohammad Mehdi
MM
Moradimogadam
Marzieh
M
Mohammadzadeh
Shiva
S